Specialty Drug Network Experts Urge Smaller Launches To Achieve Better Long-Term Access

Building a specialty drug network from scratch presents one of the most complex challenges facing healthcare strategy teams today.

Three industry voices are pushing back against the instinct to scale quickly, arguing that a more measured approach produces stronger outcomes over time.

Jon Hamrick, Rena Goins, and Bob Cochran laid out their case in the third instalment of the first episode of their ongoing executive conversation series.

Their central argument is that specialty networks should start small, a position that runs contrary to the expansionary logic that often drives pharmaceutical access strategies.

The trio identified three interconnected pressures that any specialty network must navigate carefully: access, data, and support.

Getting access right means resisting the temptation to bring too many providers or distribution points into a network before the infrastructure can adequately serve them.

Data considerations sit at the heart of the debate, since a smaller initial network generates cleaner, more actionable information that teams can actually use to refine their approach.

Support structures, the third pillar, are harder to sustain across a sprawling network, and the executives argue that quality of support deteriorates rapidly when growth outpaces operational capacity.

The conversation, published on November 12, 2026, forms part of a broader series examining what separates high-performing specialty trade teams from those that struggle to deliver consistent results.

Hamrick, Goins, and Cochran collectively suggest that the discipline required to launch small and expand deliberately is itself a marker of strategic maturity within trade and specialty pharmacy functions.

The tension between urgency, particularly when patients need access to critical therapies, and the operational case for restraint is one the speakers acknowledge directly rather than dismiss.

Their framework implies that networks which attempt to serve everyone immediately often end up serving no one particularly well, a trade-off that has real consequences for patient outcomes.

The episode reflects a growing conversation across the specialty pharmacy sector about whether the industry’s default assumptions around scale and speed are actually serving the people at the end of the supply chain.